INTERNATIONAL PATENT: AC IMMUNE SA FILES APPLICATION FOR "THERAPEUTIC USE OF NLRP3 INFLAMMASOME PATHWAY INHIBITOR COMPOUNDS"

GENEVA, March 23 -- AC IMMUNE SA (EPFL Innovation Park, Building B1015 Lausanne) filed a patent application (PCT/EP2025/075965) for "THERAPEUTIC USE OF NLRP3 INFLAMMASOME PATHWAY INHIBITOR COMPOUNDS" on Sep 11, 2025. With publication no. WO/2026/057747, the details related to the patent application was published on Mar 19, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): BASCO, Davide (c/o AC IMMUNE SA, EPFL Innovation Park, Building B1015 Lausanne)

Abstract: The present invention relates to compounds which are for use in the treatment, alleviation or prevention of obesity and/or a disease, ...